Generic versions of Trilipix debut in USA; Mylan sued by UCB

16 July 2013

Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment of authorized generic Trilipix (fenofibric acid) delayed release capsules, 45mg and 135 mg, through its generics division Global Pharmaceuticals.

Under the terms of a settlement agreement, Abbott Laboratories (now AbbVie [NYSE: ABBV]) and Fournier Laboratories Ireland granted Impax the right to sell an authorized generic as early as July 15, 2013.

Also, following final approval from the US Food and Drug Administration for its Abbreviated New Drug Application, US copy drugmaker Mylan (Nasdaq: MYL has launched fenofibric acid delayed-release capsules, 45mg and 135mg, the company said yesterday (July 15).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK